S'abonner

Safety and effectiveness of combined scoring balloon and paclitaxel-coated balloon angioplasty for stenosis in the hemodialysis access circuit - 02/01/19

Doi : 10.1016/j.diii.2018.05.014 
J. Zheng a, J. Cui b, J. Meiyan Qing c, Z. Irani d,
a Department of Radiology, Shengjing Hospital of China Medical University, 110004 Shenyang, China 
b Division of Nephrology, Department of Medicine, Massachusetts General Hospital, 02114 Boston, Massachusetts, United State of America 
c Montefiore Medical Center Radiology Department, 111E, 210th, street Bronx, 10467 New York, United State of America 
d Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, 55, Fruit street, GRB 298, 02114 Boston, Massachusetts, United State of America 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Purpose

To evaluate the safety and effectiveness of combined scoring balloon (SB) and paclitaxel-coated balloon (PCB) angioplasty for stenosis in the dysfunctional hemodialysis access circuit.

Material and methods

Patients were referred from outpatient dialysis centers by their nephrologists because of dysfunctional dialysis access circuit. Fistulogram/graftogram was performed by experienced interventional radiologists. Those with in-stent stenosis, stent edge stenosis or vessel diameter at the culprit segment larger than 6mm were excluded. Angioplasty of the stenotic segment was performed with SB and followed by PCB. All study outcomes were defined according to the Society of Interventional Radiology technology assessment committee reporting standards for percutaneous interventional procedures in dialysis access circuit.

Results

A total of 23 patients received combined SB/PCB angioplasty for stenosis of hemodialysis access circuit which included 15 fistulas and 8 grafts. There were 10 men and 13 women with a mean age of 63.3±2.7 (SD) years (range: 37–85years). The technical success and clinical success rates were both 100%. There were no complications during or after the procedures. The target lesion primary patency rates at 3, 6 and 12months were 91.3%, 69.6%, and 45.2%, respectively and the estimated median target lesion restenosis (TLR) free duration was 11.0months (95% confidence interval [CI]: 5.1–16.9months). In patients with a recurrent stenosis, the median TLR-free duration of combined angioplasty was significantly higher than that of prior angioplasty with plain balloon (10.2months [95% CI: 6.4–14.0months] vs. 4.2months [95%CI: 2.1–6.4months]) (P=0.047). The mean TLR-free duration was significantly higher in patients with a juxta-anastomotic stenosis than those with non-juxta-anastomotic lesion (21.3months [95% CI: 14.7–28.0months] vs. 8.2months [95% CI: 5.1–11.4months]) (P=0.004).

Conclusion

Combined SB/PCB angioplasty is safe and effective for the hemodialysis access stenosis.

Le texte complet de cet article est disponible en PDF.

Keywords : Angioplasty, Scoring balloon, Paclitaxel-coated balloon, Hemodialysis access circuit, Vascular stenosis


Plan


© 2018  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 100 - N° 1

P. 31-37 - janvier 2019 Retour au numéro
Article précédent Article précédent
  • Percutaneous gastric tube placement: Comparison of trans-abdominal and trans-oral approach in patients with chronic ascites
  • A. Gasparetto, M. Rosenberg, D. Hunter, J. Golzarian, D. D'Souza
| Article suivant Article suivant
  • Clinical utility of one month imaging following selective internal radiation therapy
  • S. Young, A. Taylor, J. Golzarian, S. Flanagan, D. D'Souza, T. Sanghvi

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.